capecitabine has been researched along with Digestive System Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gui, Q; Li, D; Xu, C; Zhuge, Y | 1 |
| Brixi, H; Cadiot, G; Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Legoux, JL; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T | 1 |
| André, T; Barin-Le-Guellec, C; Bouché, O; Boyer, JC; Carni, P; Ciccolini, J; Delaloge, S; Étienne-Grimaldi, MC; Faroux, R; Guigay, J; Le Malicot, K; Legoux, JL; Loriot, MA; Malka, D; Masskouri, F; Michel, P; Seitz, JF; Thariat, J; Thomas, F | 1 |
| Claringbold, PG; Kesavan, M; Turner, JH | 1 |
| Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Cheng, YC; Elligers, K; Grant, N; Jiang, ZL; Lamb, L; Lansigan, F; Liu, SH; Mezes, M; Ruta, S; Saif, MW | 1 |
1 review(s) available for capecitabine and Digestive System Neoplasms
| Article | Year |
|---|---|
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
3 trial(s) available for capecitabine and Digestive System Neoplasms
| Article | Year |
|---|---|
Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Digestive System Neoplasms; Dose-Response Relationship, Drug; Exercise Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases | 2021 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Neutrophils; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stomach Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2014 |
Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Chinese Herbal; Female; Fluorouracil; Glycyrrhiza; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paeonia; Pancreatic Neoplasms; Phytotherapy; Scutellaria baicalensis; Ziziphus | 2010 |
2 other study(ies) available for capecitabine and Digestive System Neoplasms
| Article | Year |
|---|---|
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Digestive System Neoplasms; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Propensity Score; Temozolomide | 2019 |
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biology; Biomedical Research; Breast Neoplasms; Capecitabine; Digestive System Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; France; Genotype; Health Care Surveys; Humans; Oncologists; Otorhinolaryngologic Neoplasms; Pharmacovigilance; Practice Guidelines as Topic; Pyrimidines; Reimbursement Mechanisms | 2019 |